Hofseth BioCare
(HBC)

17:37:00 · Valuta i NOK · Oslo Börs

17:37:00 · Valuta i NOK

Oslo Börs

Senast

8,60

Idag %

−1,38%

Idag +/-

−0,12

Köp

8,50

Sälj

8,60

Högst

8,60

Lägst

8,50

Omsatt (Antal)

14 440

17:37:00 · Valuta i NOK · Oslo Börs

17:37:00 · Valuta i NOK

Oslo Börs

Hofseth BioCare

17:37:00 · Oslo Börs · Valuta i NOK

17:37:00 · Valuta i NOK

Oslo Börs

Senast

8,60

Utveckling idag

−1,38%

−0,12

Köp

8,50

Sälj

8,60

Högst

8,60

Lägst

8,50

Omsatt (Antal)

14 440

Utveckling

Visa volym

Orderdjup

Stängd

Antal

Köp

9 789

Sälj

Antal

3 369

Senaste avslut

Tid	Antal	Köpare	Säljare
16:13:42	3 513	-	-
15:47:33	211	-	-
15:47:33	3 750	-	-
15:47:33	39	-	-
15:31:52	269	-	-

Volymvägt snittpris (VWAP)

8,53

VWAP

8,53

Omsättning (NOK)

123 186

Mäklarstatistik

Ingen data hittades

Företagshändelser

Det finns inga angivna utdelningar

Nyheter & Pressmeddelande

Utveckling

Visa volym

Inga Nordnet Markets Certifikat finns med underliggande värdepapper.

Nyheter & Pressmeddelande

Företagshändelser

Det finns inga angivna utdelningar

Orderdjup

Stängd

Antal

Köp

9 789

Sälj

Antal

3 369

Senaste avslut

Tid	Antal	Köpare	Säljare
16:13:42	3 513	-	-
15:47:33	211	-	-
15:47:33	3 750	-	-
15:47:33	39	-	-
15:31:52	269	-	-

Volymvägt snittpris (VWAP)

8,53

VWAP

8,53

Omsättning (NOK)

123 186

Mäklarstatistik

Ingen data hittades

Företagshändelser

Det finns inga angivna utdelningar

*Kommentarerna ovan kommer från shareville.se och har varken redigerats eller granskats av Nordnet. De innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna.

Nyckeldata

P/E
-
P/E*
-
P/B
-
P/S
-
Utdelning/aktie
-
EPS
-
Direktavkastning
-
EPS tillväxt*
-
PEG
-

*Baserat på estimat

Finansiell översikt

Morningstar faktablad

Resultaträkning ()

category_local

Balansräkning ()

category_local

Kassaflöde ()

category_local

Bolagsöversikt

Företagsnamn	-
VD	-
E-post	-
Hemsida	-
Säte	-
Antal anställda	-
Antal aktier	-
Börsvärde	-

Om värdepapperet

Namn	Hofseth BioCare
ISIN	-
Sektor	-
Bransch	-
Kortnamn	HBC
Introduktionsdatum	-
Belåningsgrad	-
Säkerhetskrav	200%

NorwayHofseth BioCare(HBC)

NorwayHofseth BioCare

Hofseth Biocare ASA: HBC starts its accelerated COVID-19 Phase 2 clinical trial of OmeGo® salmon oil to decrease Acute Respiratory Distress Syndrome and the need for assisted respiration

Hofseth Biocare ASA: HBC har startet protokollutvikling for en akselerert klinisk fase 2-studie med OmeGo® for å redusere akutt lungesvikt og behovet for kunstig åndedrett hos COVID-19 pasienter

Hofseth Biocare ASA: HBC has begun protocol development for its accelerated Phase 2 clinical trial with OmeGo® to decrease Acute Respiratory Distress Syndrome and the need for assisted respiration in COVID-19 patients

Hofseth Biocare ASA: Completed Annual General Meeting

Hofseth Biocare ASA:

Hofseth Biocare ASA: Proxy Rights at Annual General Meeting

Hofseth Biocare ASA: Preclinical research with OmeGo® demonstrates potential to treat eosinophilic asthma

Hofseth Biocare ASA: First Quarter 2020 Financial Report

Hofseth Biocare ASA: Two-year research collaboration contract signed with Stanford on the use of Salmon Protein Hydrolysate peptides for the treatment of GI tract diseases in children and adults

Hofseth Biocare ASA: Notice of Annual General Meeting 2020

Mest handlade

Hofseth Biocare ASA: HBC starts its accelerated COVID-19 Phase 2 clinical trial of OmeGo® salmon oil to decrease Acute Respiratory Distress Syndrome and the need for assisted respiration

Hofseth Biocare ASA: HBC har startet protokollutvikling for en akselerert klinisk fase 2-studie med OmeGo® for å redusere akutt lungesvikt og behovet for kunstig åndedrett hos COVID-19 pasienter

Hofseth Biocare ASA: HBC has begun protocol development for its accelerated Phase 2 clinical trial with OmeGo® to decrease Acute Respiratory Distress Syndrome and the need for assisted respiration in COVID-19 patients

Hofseth Biocare ASA: Completed Annual General Meeting

Hofseth Biocare ASA:

Hofseth Biocare ASA: Proxy Rights at Annual General Meeting

Hofseth Biocare ASA: Preclinical research with OmeGo® demonstrates potential to treat eosinophilic asthma

Hofseth Biocare ASA: First Quarter 2020 Financial Report

Hofseth Biocare ASA: Two-year research collaboration contract signed with Stanford on the use of Salmon Protein Hydrolysate peptides for the treatment of GI tract diseases in children and adults

Hofseth Biocare ASA: Notice of Annual General Meeting 2020

Hofseth Biocare ASA: HBC starts its accelerated COVID-19 Phase 2 clinical trial of OmeGo® salmon oil to decrease Acute Respiratory Distress Syndrome and the need for assisted respiration

Hofseth Biocare ASA: HBC har startet protokollutvikling for en akselerert klinisk fase 2-studie med OmeGo® for å redusere akutt lungesvikt og behovet for kunstig åndedrett hos COVID-19 pasienter

Hofseth Biocare ASA: HBC has begun protocol development for its accelerated Phase 2 clinical trial with OmeGo® to decrease Acute Respiratory Distress Syndrome and the need for assisted respiration in COVID-19 patients

Hofseth Biocare ASA: Completed Annual General Meeting

Hofseth Biocare ASA:

Hofseth Biocare ASA: Proxy Rights at Annual General Meeting

Hofseth Biocare ASA: Preclinical research with OmeGo® demonstrates potential to treat eosinophilic asthma

Hofseth Biocare ASA: First Quarter 2020 Financial Report

Hofseth Biocare ASA: Two-year research collaboration contract signed with Stanford on the use of Salmon Protein Hydrolysate peptides for the treatment of GI tract diseases in children and adults

Hofseth Biocare ASA: Notice of Annual General Meeting 2020

Resultaträkning ()

Balansräkning ()

Kassaflöde ()

Om värdepapperet

Hofseth BioCare
(HBC)

Hofseth BioCare